{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Liu W"],"funding":["National Natural Science Foundation of China"],"pubmed_abstract":["<h4>Background</h4>Sepsis-induced cardiomyopathy (<i>SIC</i>) is one major cause of death for sepsis but lacks timely diagnosis and specific treatment due to unclear mechanisms. Lipocalin-2 (LCN-2) is a key regulator of lipid metabolism which has been recently proved closely related to sepsis, however, the relationship between LCN-2 and septic myocardial injury remains unknown. We aim to explore the role of LCN-2 in the pathological progress of <i>SIC</i> based on clinical and laboratory evidence.<h4>Methods</h4>Consecutive patients admitted to the intensive care unit (ICU) from August 2021 to April 2022 fulfilling the criteria of severe sepsis were included. The level of LCN-2 in plasma was assayed and analyzed with clinical characteristics. Biostatistical analysis was performed for furth"],"journal":["Frontiers in cardiovascular medicine"],"pagination":["1009726"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9676239"],"repository":["biostudies-literature"],"pubmed_title":["Lipocalin-2 participates in sepsis-induced myocardial injury by mediating lipid accumulation and mitochondrial dysfunction."],"pmcid":["PMC9676239"],"pubmed_authors":["Li S","Guo X","Hong T","Shen Y","He B","Zhang Q","Liu W","Jin L","Su F"],"additional_accession":[]},"is_claimable":false,"name":"Lipocalin-2 participates in sepsis-induced myocardial injury by mediating lipid accumulation and mitochondrial dysfunction.","description":"<h4>Background</h4>Sepsis-induced cardiomyopathy (<i>SIC</i>) is one major cause of death for sepsis but lacks timely diagnosis and specific treatment due to unclear mechanisms. Lipocalin-2 (LCN-2) is a key regulator of lipid metabolism which has been recently proved closely related to sepsis, however, the relationship between LCN-2 and septic myocardial injury remains unknown. We aim to explore the role of LCN-2 in the pathological progress of <i>SIC</i> based on clinical and laboratory evidence.<h4>Methods</h4>Consecutive patients admitted to the intensive care unit (ICU) from August 2021 to April 2022 fulfilling the criteria of severe sepsis were included. The level of LCN-2 in plasma was assayed and analyzed with clinical characteristics. Biostatistical analysis was performed for furth","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-07-14T17:36:53.298Z","creation":"2025-04-19T14:44:15.395Z"},"accession":"S-EPMC9676239","cross_references":{"pubmed":["36419491"],"doi":["10.3389/fcvm.2022.1009726"]}}